Hexamethylenetetramines Patents (Class 514/244)
  • Patent number: 10973800
    Abstract: The invention relates to salvinorin compositions and uses thereof. Specifically, the invention relates to administering a salvinorin compound to produce vasodilatory effect and organ protective effect from hypoxia/ischemia and reperfusion. The invention further relates to treating various diseases or disorders.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: April 13, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventor: Renyu Liu
  • Patent number: 8969345
    Abstract: A dibenzoxepin derivative represented by the following general formula (I) wherein Y is a hydrogen atom and the like, RA is a hydrogen atom and the like, X is the formula (b3) wherein RB is a hydrogen atom and the like, and the like, A is the formula (a18) wherein R1 is a hydrogen atom and the like, and RC and RD are the same or different and each is a hydrogen atom and the like, and the like, which has a PPAR? agonist activity and the like, and useful as a therapeutic agent and/or prophylaxis agent and the like for type 2 diabetes and the like, or a pharmaceutically acceptable salt thereof and the like is provided.
    Type: Grant
    Filed: August 3, 2012
    Date of Patent: March 3, 2015
    Assignee: Kyowa Hakko Kirin Co., Ltd.
    Inventors: Keisuke Yamamoto, Tomohiro Tamura, Rina Nakamura, Kimihisa Ueno, Shintaro Hosoe
  • Publication number: 20150038480
    Abstract: The invention provides methods of preventing, treating or ameliorating autoimmune diseases, such as diabetes and celiac disease, by decreasing the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease by the administration of small organic compounds. The invention also provides pharmaceutical compositions comprising the therapeutically effective small organic compounds and methods of using the same.
    Type: Application
    Filed: May 29, 2012
    Publication date: February 5, 2015
    Applicants: UNIVERSITY OF FLORIDA RESERCH FOUNDATION INCORPORTED, THE REGENTS OF THE UNIVERSITY OF COLORADO, a body corporate
    Inventors: Aaron Michels, Maki Nakayama, David Ostrov
  • Patent number: 8900613
    Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: December 2, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Bei Yin, Freddie L. Singleton
  • Patent number: 8754083
    Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: June 17, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Bei Yin, Freddie L. Singleton
  • Patent number: 8747873
    Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: June 10, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Bei Yin, Freddie L. Singleton
  • Patent number: 8748427
    Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: June 10, 2014
    Assignee: Dow Global Technologies LLC
    Inventors: Bei Yin, Freddie L. Singleton
  • Publication number: 20140134275
    Abstract: The invention features compositions and methods that are useful for the treatment of neoplasia (e.g., pancreatic cancer, colon cancer, brain cancer) by increasing DNA damage, reducing nucleotide synthesis, and reducing base excision repair (BER).
    Type: Application
    Filed: April 20, 2012
    Publication date: May 15, 2014
    Applicant: University of Florida Research Foundation
    Inventors: Satya Narayan, Aruna S. Jaiswal, David A. Ostov, Sukwon Hong
  • Publication number: 20140135334
    Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.
    Type: Application
    Filed: November 15, 2013
    Publication date: May 15, 2014
    Inventors: Bei Yin, Freddie L. Singleton
  • Publication number: 20140073646
    Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.
    Type: Application
    Filed: November 15, 2013
    Publication date: March 13, 2014
    Inventors: Bei Yin, Freddie L. Singleton
  • Patent number: 8623854
    Abstract: A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase II? and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo II? have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: January 7, 2014
    Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of Florida Research Foundation, Inc.
    Inventors: Daniel M. Sullivan, Joel G. Turner, Thomas C. Rowe, David A. Ostrov
  • Patent number: 8592396
    Abstract: Compounds are provided which are activators of the enzyme glucokinase and thus are useful in treating diabetes and related diseases, which compounds have the structure wherein R1, R2, R3, R4, R5, R6, Y and X are as defined herein or a pharmaceutically acceptable salt thereof. A method for treating diabetes and related disease employing the above compounds is also provided.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: November 26, 2013
    Assignee: Bristol-Myers Squibb Company
    Inventors: Wei Meng, Peter T. W. Cheng
  • Patent number: 8466129
    Abstract: The present invention relates to methods of preventing airway remodeling using A2B adenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other pulmonary diseases. The invention also relates to pharmaceutical compositions for use in the method.
    Type: Grant
    Filed: October 26, 2009
    Date of Patent: June 18, 2013
    Assignee: Gilead Sciences, Inc.
    Inventors: Dewan Zeng, Michael R. Blackburn, Luiz Belardinelli
  • Publication number: 20130079297
    Abstract: The invention relates to phosphorylation inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating cell proliferative disorders, especially cancer.
    Type: Application
    Filed: November 19, 2012
    Publication date: March 28, 2013
    Applicant: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION
    Inventor: UNIVERSITY OF FLORIDA RESEARCH FOUNDA
  • Patent number: 8349834
    Abstract: This invention relates to certain unsaturated fatty acid derivatives of therapeutically active 1,3-dioxolane nucleoside analogues and to pharmaceutical formulations containing them. The said derivatives fall within formula (I). Compounds of formula (I) can be used in the treatment of a cancerous disease, including solid tumors and haematological cancers such as leukaemias, lymphomas and multiple myelomas.
    Type: Grant
    Filed: December 7, 2006
    Date of Patent: January 8, 2013
    Assignee: Clavis Pharma AS
    Inventors: Finn Myhren, Marit Liland Sandvold, Steinar Hagen, Ole Henrik Eriksen
  • Patent number: 8222250
    Abstract: Compositions of 1-(3-chloroallyl)-3,5,7-triaza-1-azonia-adamantane chloride, and an optional second biocide, in copolymers of ethylene oxide/propylene oxide are provided. The compositions exhibit good color and phase stability.
    Type: Grant
    Filed: June 26, 2009
    Date of Patent: July 17, 2012
    Assignee: Dow Global Technologies LLC
    Inventors: Ioana Annis, Suzanne DeBruhl, Heidie M. Jevey, Jon B. Raymond
  • Publication number: 20120141491
    Abstract: The subject application provides small compounds that are able to increase/enhance autophagy in various cells. These compounds are useful in augmenting existing treatments of various cancers, microbial/viral infections, and neurodegenerative diseases. Thus, the subject application also provides methods of treating various types of cancers, microbial/viral infections, and neurodegenerative diseases.
    Type: Application
    Filed: August 9, 2010
    Publication date: June 7, 2012
    Applicant: University of Florida Research Foundation Inc.
    Inventors: William A. Dunn, Debra Everton Akin, Brian Keith Law
  • Publication number: 20120129861
    Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.
    Type: Application
    Filed: September 27, 2010
    Publication date: May 24, 2012
    Inventors: Bei Yin, Freddie L. Singleton
  • Publication number: 20120100227
    Abstract: The invention relates to protein binding inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating a variety of diseases and disorders, including cell proliferative disorders, especially cancer.
    Type: Application
    Filed: March 4, 2010
    Publication date: April 26, 2012
    Applicant: University of Florida Research Foundation
    Inventors: Vita Golubovskaya, David A. Ostrov, William G. Cance
  • Patent number: 8163865
    Abstract: Biocompatible amino acid anhydride polymers for use in tissue engineering, and methods for their preparation and use.
    Type: Grant
    Filed: August 6, 2009
    Date of Patent: April 24, 2012
    Assignee: University of Washington
    Inventors: Shrojalkumar M. Desai, Buddy D. Ratner
  • Patent number: 8163911
    Abstract: The invention relates to substituted arylsulphonylaminomethylphosphonic acid derivatives of general formula (I) wherein the groups Ra to Rf, A and Z are defined as mentioned in the specification and claims, which are suitable for preparing a medicament for the treatment of metabolic disorders, particularly type 1 or type 2 diabetes mellitus.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: April 24, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Elke Langkopf, Alexander Pautsch, Corinna Schoelch, Annette Schuler-Metz, Ruediger Streicher, Holger Wagner
  • Publication number: 20120046246
    Abstract: This invention relates to therapeutic methods for treating or preventing an osteoclast-related disease or disorder in a subject identified as in need of a treatment of bone diseases, compounds for such uses, and compositions thereof.
    Type: Application
    Filed: December 18, 2009
    Publication date: February 23, 2012
    Applicant: University of Florida Research Foundation
    Inventors: Lexie Shannon Holliday, David A. Ostrov
  • Publication number: 20110275581
    Abstract: A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase II? and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind to the two nuclear export sequences (NES) topo II? have been identified from the NCI database using computer-generated molecular modeling. These SMI will improve the effectiveness of topo II directed therapeutics, particularly in the treatment of diseases such as multiple myeloma (MM). In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II.
    Type: Application
    Filed: June 13, 2011
    Publication date: November 10, 2011
    Applicants: University of Florida Research Foundation, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Daniel M. Sullivan, Joel G. Turner, Thomas C. Rowe, David A. Ostrov
  • Publication number: 20110070179
    Abstract: Compositions are disclosed comprising novel fluorinated cationic alcohols in a cosmetically acceptable vehicle. The fluorinated compounds alter a surface property of the hair to provide hair conditioning, for example. In embodiments, the compounds have improved water solubility and deposition properties.
    Type: Application
    Filed: September 16, 2010
    Publication date: March 24, 2011
    Applicant: Living Proof, Inc.
    Inventors: David T. Puerta, Lorna Nagamoottoo-Casse, Kevin T. Love
  • Patent number: 7858625
    Abstract: This invention features conjugates, compositions, methods of synthesis, and applications thereof, including folate derived conjugates of nucleosides, nucleotides, non-nucleosides, and nucleic acids including enzymatic nucleic acids and antisense nucleic acid molecules.
    Type: Grant
    Filed: June 24, 2005
    Date of Patent: December 28, 2010
    Assignee: Sirna Therapeutics, Inc.
    Inventors: Jasenka Matulic-Adamic, Leonid Beigelman
  • Publication number: 20100310680
    Abstract: This invention relates to a novel composition and method useful for the treatment of acne, and more particularly, to a composition and method for reducing an appearance of post acne marks and scars without skin irritation in a short amount of time.
    Type: Application
    Filed: June 9, 2009
    Publication date: December 9, 2010
    Inventors: Theresa Chen, Geraldine Watson, I-Ting Wu
  • Publication number: 20100166886
    Abstract: The invention features a method of (i) reducing the appearance of pores or oil on the skin and (ii) evening skin tone or smoothing skin by applying to an area of skin in need of such treatment a composition including an anti-acne agent, an antimicrobial agent, and a lactate.
    Type: Application
    Filed: March 12, 2010
    Publication date: July 1, 2010
    Inventors: Jeffrey M. Wu, Jue-Chen Liu, Jeannette Chantalat, Ying Sun, Stefanie A. Johnsen, Hanuman B. Jampani
  • Patent number: 7745442
    Abstract: Prophylactic treatment methods are provided for protection of individuals and/or populations against infection from airborne pathogens. In particular, prophylactic treatment methods are provided including administering a sodium channel blocker or pharmaceutically acceptable salts thereof to one or more members of a population at risk of exposure to or already exposed to one or more airborne pathogens, either from natural sources or from intentional release of pathogens into the environment.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: June 29, 2010
    Assignee: Parion Sciences, Inc.
    Inventors: Michael R. Johnson, Samuel E. Hopkins
  • Publication number: 20090325965
    Abstract: Compositions of 1-(3-chloroallyl)-3,5,7-triaza-1-azonia-adamantane chloride, and an optional second biocide, in copolymers of ethylene oxide/propylene oxide are provided. The compositions exhibit good color and phase stability.
    Type: Application
    Filed: June 26, 2009
    Publication date: December 31, 2009
    Inventors: Ioana Annis, Suzanne DeBruhl, Heidie M. Jevey, Jon B. Raymond
  • Publication number: 20090191285
    Abstract: A moisturizing liquid liner composition comprising a hydrophobic moiety and an emulsifier is described. Further, a substrate comprising a barrier layer and a moisturizing liquid liner composition comprising a hydrophobic moiety and an emulsifier is described. The substrate may be incorporated into an article.
    Type: Application
    Filed: January 30, 2008
    Publication date: July 30, 2009
    Applicant: Evonik Degussa Corporation
    Inventors: Anna HOWE, Dana Adkins, Scott W. Wenzel, David William Koenig, Douglas R. Hoffman
  • Patent number: 7507734
    Abstract: Disclosed are compounds according to the general formula (I), where the definitions of the substituents X, R1 and R2 are detailed in the description, as well as their physiologically acceptable salts and solvate, methods for producing these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).
    Type: Grant
    Filed: November 16, 2006
    Date of Patent: March 24, 2009
    Assignee: Aventis Pharma S.A.
    Inventors: Swen Hoelder, Gunter Muller, Karl Schoenafinger, David William Will, Hans Matter, Martin Bossart, Cecile Combeau, Christine Delaisi, Ingrid Sassoon, Anke Steinmetz, Didier Benard
  • Patent number: 7323449
    Abstract: The present invention provides thionucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B polymerase, as inhibitors of HCV replication, and/or for the treatment of hepatitis C infection. The invention also describes pharmaceutical compositions containing such thionucleoside compounds alone or in combination with other agents active against RNA-dependent RNA viral infection, in particular HCV infection. Also disclosed are methods of inhibiting RNA-dependent RNA polymerase, inhibiting RNA-dependent RNA viral replication, and/or treating RNA-dependent RNA viral infection with the thionucleoside compounds of the present invention.
    Type: Grant
    Filed: July 18, 2003
    Date of Patent: January 29, 2008
    Assignees: Merck & Co., Inc., Isis Pharmaceuticals, Inc.
    Inventors: David B. Olsen, Balkrishen Bhat, Phillip Dan Cook
  • Patent number: 7157078
    Abstract: This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about 50 to about 100% of termites within about 24 to about 84 days after the termites begin to ingest the termiticide or the bait matrix comprising the termiticide, b) a cellulose containing material, and c) water. The termiticidal bait matrix can be used in a bait station installed in the ground. The kits are suitable to be used by consumers in their homes.
    Type: Grant
    Filed: February 2, 2004
    Date of Patent: January 2, 2007
    Assignee: The University of Florida Research Foundation, Inc.
    Inventors: Philip Frederick Brode, III, Garry Steven Garren, Leo Timothy Laughlin, Randall Stryker Matthews, Dale Edwin Barker, Daniel James Kinne, Gary Eugene McKibben, Christopher Miles Miller, Timothy Robert Probst
  • Patent number: 7097860
    Abstract: A method of reducing inflammation in a variety of disorders by using an intraperitoneal solution of magnesium. The solution can be used for treating inflammatory and inflammation-related disorders in animals and/or humans. Application of the solution reduces inflammation and thereby assists in the healing process. An alternative method involves the intraperitoneal administration of a solution containing magnesium salts. Another alternative method provides for treatment of inflammatory and inflammation-related disorders in animals by way of intraperitoneal administration of a solution containing magnesium salts, methenamine or its salts and dextrose. The method further provides the use of methenamine or its salts and/or dextrose in combination with magnesium.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: August 29, 2006
    Inventors: Aaron Moshenyat, Anna Moshenyat, Reuven Moshenyat, Yitzchak Moshenyat
  • Patent number: 7045531
    Abstract: The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions. Methods and compositions for treatment of conditions caused by amyloidosis, A?-mediated ROS formation, or both, such as Alzheimer's disease, are disclosed.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: May 16, 2006
    Assignee: The General Hospital Corporation
    Inventors: Ashley I. Bush, Xudong Huang, Craig S. Atwood, Rudolph E. Tanzi
  • Patent number: 7008903
    Abstract: The present invention provides a composition comprising synergistic amounts of a compound of the formula (I) wherein X, E, R, A and Z are as defined herein, and at least one fungicidal active compound as defined herein. The compositions of the present invention find use as pesticides.
    Type: Grant
    Filed: June 3, 2002
    Date of Patent: March 7, 2006
    Assignee: Bayer Aktiengesellschaft
    Inventors: Stefan Dutzmann, Christoph Erdelen, Wolfram Andersch, Heinz-Wilhelm Dehne, Jürgen Hartwig, Klaus Stenzel, Wolfgang Krämer
  • Patent number: 6716421
    Abstract: This invention relates to devices, kits, and methods for eliminating termite colonies. The kits, devices, and methods employ a termiticidal bait matrix containing a) a termiticide selected such that the termiticide causes death to about 50 to about 100% of termites within about 24 to about 84 days after the termites begin to ingest the termiticide or the bait matrix comprising the termiticide, b) a cellulose containing material, and c) water. The termiticidal bait matrix can be used in a bait station installed in the ground. The kits are suitable to be used by consumers in their homes.
    Type: Grant
    Filed: March 5, 2001
    Date of Patent: April 6, 2004
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Philip Frederick Brode, III, Garry Steven Garrett, Leo Timothy Laughlin, Randall Stryker Matthews, Dale Edwin Barker, Daniel James Kinne, Gary Eugene McKibben, Christopher Miles Miller, Timothy Robert Probst
  • Patent number: 6576633
    Abstract: Anhydrous, liquid antimicrobial compositions comprising quaternaries 1-(benzyl)-3,5,7-triaza-1-azoniaadamantane chloride, 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane chloride and the cis- and cis/trans-isomers thereof, 1-(&agr;-(2-xylyl))-3,5,7-triaza-1-azoniaadamantane chloride and methyl 1-(3,5,7-triaza-1-azoniaadamantane chloride) acetate in admixture with an anhydrous carrier liquid and a thixotropic material are substantially stable to color changes, physical changes and/or chemical changes while under conventional storage conditions for extended time periods.
    Type: Grant
    Filed: February 22, 1996
    Date of Patent: June 10, 2003
    Assignee: The Dow Chemical Company
    Inventors: Tracy L. Young, Philip J. Brondsema
  • Publication number: 20030018032
    Abstract: Substituted bicyclic imidazo-3-yl-amines and medicaments comprising these compounds, useful, inter alia, as analgesics.
    Type: Application
    Filed: April 8, 2002
    Publication date: January 23, 2003
    Applicant: GRUENENTHAL GMBH
    Inventors: Matthias Gerlach, Corinna Maul
  • Publication number: 20020197245
    Abstract: Antitumor combinations consisting of taxol or Taxotere or analogues thereof combined with at least one therapeutically useful substance for treating neoplastic diseases.
    Type: Application
    Filed: April 30, 2002
    Publication date: December 26, 2002
    Applicant: Aventis Pharma, S.A.
    Inventor: Marie-Christine Bissery
  • Patent number: 6369051
    Abstract: This invention comprises methods of depression, anxiety, generalized anxiety disorder (GAD), hot flush, post partum depression, premenstrual syndrome, obesity, obsessive compulsive disorder, post-traumatic stress disorder, social phobia, disruptive behavior disorders, impulse control disorders, borderline personality disorder, chronic fatigue disorder, premature ejaculation, pain, attention deficit disorders, with and without hyperactivity, Gilles de la Tourette syndrome, bulimia nervosa, or Shy Drager Syndrome comprising administration of a selective serotonin reuptake inhibitor and compound of the formulae I or II: wherein Z is a moiety selected from the group of: wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, benzyloxy, or halogen; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated e
    Type: Grant
    Filed: June 29, 2001
    Date of Patent: April 9, 2002
    Assignee: American Home Products Corporation
    Inventor: Simon Nicholas Jenkins
  • Patent number: 6340679
    Abstract: The present invention relates to acylguanidine derivatives of the formula I in which R1, R2, R4, Ar, X and n have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of the formula I are valuable pharmacologically active compounds. They are vitronectin receptor antagonists and inhibitors of cell adhesion. They inhibit, for example, bone resorption by osteoclasts and are suitable for the therapy and prophylaxis of diseases which are caused at least partially by an undesired extent of bone resorption, for example osteoporosis. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceutical preparations, and pharmaceutical preparations comprising them.
    Type: Grant
    Filed: February 11, 2000
    Date of Patent: January 22, 2002
    Assignees: Aventis Pharma Deutschland GmbH, Genentech, Inc.
    Inventors: Anuschirwan Peyman, Jochen Knolle, Karl-Heinz Scheunemann, David William Will, Denis Carniato, Jean-Francois Gourvest, Thomas R. Gadek, Sarah Catherine Bodary
  • Publication number: 20010046995
    Abstract: Skin protection agents such as topical compositions which can prevent the passage of toxic chemicals through the skin, such as barrier creams. Formulations may contain hexamethylene tetramine or derivatives or analogues thereof, which react with alkylating agents such as sulfur mustard, and which are suitable for formulation into topical compositions. The formulations additionally may contain perfluorinated polymeric compounds which are effective barrier compounds for a range of toxic chemicals.
    Type: Application
    Filed: January 23, 2001
    Publication date: November 29, 2001
    Applicant: The Secretary of State for Defence, Great Britain and Northern Ireland
    Inventors: John Jenner, Colin N. Smith, Robert P. Chilcott, Christopher D. Lindsay
  • Patent number: 6323218
    Abstract: The invention relates to the identification of pharmacological agents to be used in the treatment of Alzheimer's disease and related pathological conditions and compositions for treatment of conditions caused by amyloidosis, A&bgr;-mediated formation of ROS, or both, such as Alzheimer's disease.
    Type: Grant
    Filed: March 11, 1998
    Date of Patent: November 27, 2001
    Assignee: The General Hospital Corporation
    Inventors: Ashley I. Bush, Xudong Huang, Craig S. Atwood, Rudolph E. Tanzi
  • Patent number: 6251916
    Abstract: The present invention provides novel compounds and pharmaceutical compositions thereof useful in the treatment of pain. The compounds of the present invention are azaadamantanes, azanoradamantanes and azahomoadamantanes.
    Type: Grant
    Filed: May 9, 2000
    Date of Patent: June 26, 2001
    Assignee: UCB, S. A.
    Inventors: Gurmit Grewal, Anna Toy-Palmer, Xiong Cai, George Mark Latham
  • Patent number: 6183729
    Abstract: The present invention discloses stable vitamin C concentrates suitable for use in a multichamber dispenser. The compositions have a pH above about 5 and preferably should contain a xanthan and/or a carbomer as a viscosifier.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: February 6, 2001
    Assignee: Cosmoferm B.V.
    Inventors: Bertus Noordam, Luppo Edens
  • Patent number: 6043243
    Abstract: A pyrrolidine derivative or a salt thereof expressed by the following formula 1: ##STR1## wherein R.sub.1 is an alkenyl group; R.sub.2 is a lower alkoxy group or a halogen atom;R.sub.3 is a lower alkyl group;X is a group expressed by --O-- or --S--;Y is carbon or nitrogen atom;m is an integer of 1 to 3; andn is an integer of 0 to 2.The pyrrolidine derivative has an anti-ulcer effect or an antibacterial activity against Helicobacter pyroli, and has also high safety to be available for prevention or cure of ulcers.
    Type: Grant
    Filed: December 3, 1998
    Date of Patent: March 28, 2000
    Assignee: Shiseido Co., Ltd.
    Inventors: Chikao Nishino, Tomohiro Uetake
  • Patent number: 5716629
    Abstract: The invention is a composition for controlling microbiological growth which comprises a combination of 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane and tetrahydro-3,5-dimethyl-2H-1,3,5-thiadiazine-2-thione. The invention has particular utility as a composition for controlling microbiological growth in a slurry of paper machine additives such as precipitated calcium carbonate which comprises adding to said slurry a combination of 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane and tetrahydro-3,5-dimethyl-2H-1,3,5-thiadiazine-2-thione.The invention is also a method for controlling bacterial and fungal growth which comprises a combination of 1-(3-chloroallyl)-3,5,7-triaza-1-azoniaadamantane and tetrahydro-3,5-dimethyl-2H-1,3,5-thiadiazine-2-thione.
    Type: Grant
    Filed: August 8, 1996
    Date of Patent: February 10, 1998
    Assignee: Nalco Chemical Company
    Inventors: Linda R. Robertson, Sasireka S. Ramesh
  • Patent number: 5668083
    Abstract: 3-Isothiazolone compositions which are stable, free from turbidity, and do not corrode metal storage containers are disclosed. These compositions further have no possibility of coagulating latex or generating nitrosamine.
    Type: Grant
    Filed: July 18, 1996
    Date of Patent: September 16, 1997
    Assignee: Rohm and Haas Company
    Inventor: Masahiro Matsumoto
  • Patent number: 5637587
    Abstract: This invention provides a surprisingly efficacious combination useful for inhibiting microorganism growth, particularly in aqueous slurries containing mineral ore. In particular embodiments, the invention provides an antimicrobial composition comprising 1-(3-chloroallyl)-3,5,7 triaza-1-azoniaadamantane chloride and 2-bromo-2-nitropropane-1,3-diol. The invention also provides a method for inhibiting microbial growth in an aqueus mineral or ore slurry, e.g. a kaolin slurry. The method includes the step of adding to the slurry a microbiocidal composition of 1-(3-chloroallyl)-3,5,7 triaza-1-azoniaadamantane chloride and 2-bromo-2-nitropropane-1,3-diol.
    Type: Grant
    Filed: February 7, 1996
    Date of Patent: June 10, 1997
    Assignee: Nalco Chemical Company
    Inventors: Anthony E. Gross, Nancy L. Casselman